id,Provider ID,Measure ID,Measure Name,Score,n_score,sample
,340003,EDV,Emergency department volume,20000,0.333333333,
,340013,EDV,Emergency department volume,20000,0.333333333,
,340017,EDV,Emergency department volume,20000,0.333333333,
,340020,EDV,Emergency department volume,20000,0.333333333,
,340023,EDV,Emergency department volume,20000,0.333333333,
,340024,EDV,Emergency department volume,20000,0.333333333,
,340037,EDV,Emergency department volume,20000,0.333333333,
,340041,EDV,Emergency department volume,20000,0.333333333,
,340051,EDV,Emergency department volume,20000,0.333333333,
,340060,EDV,Emergency department volume,20000,0.333333333,
,340064,EDV,Emergency department volume,20000,0.333333333,
,340068,EDV,Emergency department volume,20000,0.333333333,
,340085,EDV,Emergency department volume,20000,0.333333333,
,340087,EDV,Emergency department volume,20000,0.333333333,
,340096,EDV,Emergency department volume,20000,0.333333333,
,340097,EDV,Emergency department volume,20000,0.333333333,
,340099,EDV,Emergency department volume,20000,0.333333333,
,340107,EDV,Emergency department volume,20000,0.333333333,
,340119,EDV,Emergency department volume,20000,0.333333333,
,340120,EDV,Emergency department volume,20000,0.333333333,
,340127,EDV,Emergency department volume,20000,0.333333333,
,340129,EDV,Emergency department volume,20000,0.333333333,
,340132,EDV,Emergency department volume,20000,0.333333333,
,340144,EDV,Emergency department volume,20000,0.333333333,
,340158,EDV,Emergency department volume,20000,0.333333333,
,340159,EDV,Emergency department volume,20000,0.333333333,
,340183,EDV,Emergency department volume,20000,0.333333333,
,340184,EDV,Emergency department volume,20000,0.333333333,
,340186,EDV,Emergency department volume,20000,0.333333333,
,341324,EDV,Emergency department volume,20000,0.333333333,
,340016,EDV,Emergency department volume,0,0,
,340084,EDV,Emergency department volume,0,0,
,340106,EDV,Emergency department volume,0,0,
,340133,EDV,Emergency department volume,0,0,
,340187,EDV,Emergency department volume,0,0,
,341304,EDV,Emergency department volume,0,0,
,341318,EDV,Emergency department volume,0,0,
,341319,EDV,Emergency department volume,0,0,
,341326,EDV,Emergency department volume,0,0,
,341328,EDV,Emergency department volume,0,0,
,341329,EDV,Emergency department volume,0,0,
,340008,EDV,Emergency department volume,40000,0.666666667,
,340015,EDV,Emergency department volume,40000,0.666666667,
,340027,EDV,Emergency department volume,40000,0.666666667,
,340039,EDV,Emergency department volume,40000,0.666666667,
,340061,EDV,Emergency department volume,40000,0.666666667,
,340071,EDV,Emergency department volume,40000,0.666666667,
,340073,EDV,Emergency department volume,40000,0.666666667,
,340075,EDV,Emergency department volume,40000,0.666666667,
,340109,EDV,Emergency department volume,40000,0.666666667,
,340114,EDV,Emergency department volume,40000,0.666666667,
,340116,EDV,Emergency department volume,40000,0.666666667,
,340123,EDV,Emergency department volume,40000,0.666666667,
,340126,EDV,Emergency department volume,40000,0.666666667,
,340142,EDV,Emergency department volume,40000,0.666666667,
,340143,EDV,Emergency department volume,40000,0.666666667,
,340145,EDV,Emergency department volume,40000,0.666666667,
,340151,EDV,Emergency department volume,40000,0.666666667,
,340171,EDV,Emergency department volume,40000,0.666666667,
,340001,EDV,Emergency department volume,60000,1,
,340002,EDV,Emergency department volume,60000,1,
,340004,EDV,Emergency department volume,60000,1,
,340010,EDV,Emergency department volume,60000,1,
,340014,EDV,Emergency department volume,60000,1,
,340021,EDV,Emergency department volume,60000,1,
,340028,EDV,Emergency department volume,60000,1,
,340030,EDV,Emergency department volume,60000,1,
,340032,EDV,Emergency department volume,60000,1,
,340040,EDV,Emergency department volume,60000,1,
,340042,EDV,Emergency department volume,60000,1,
,340047,EDV,Emergency department volume,60000,1,
,340050,EDV,Emergency department volume,60000,1,
,340053,EDV,Emergency department volume,60000,1,
,340069,EDV,Emergency department volume,60000,1,
,340070,EDV,Emergency department volume,60000,1,
,340090,EDV,Emergency department volume,60000,1,
,340091,EDV,Emergency department volume,60000,1,
,340098,EDV,Emergency department volume,60000,1,
,340113,EDV,Emergency department volume,60000,1,
,340115,EDV,Emergency department volume,60000,1,
,340130,EDV,Emergency department volume,60000,1,
,340131,EDV,Emergency department volume,60000,1,
,340141,EDV,Emergency department volume,60000,1,
,340147,EDV,Emergency department volume,60000,1,
,340155,EDV,Emergency department volume,60000,1,
,340166,EDV,Emergency department volume,60000,1,
,340173,EDV,Emergency department volume,60000,1,
,340042,ED_1b,ED1,492,1,
,340028,ED_1b,ED1,464,0.909385113,
,340040,ED_1b,ED1,426,0.786407767,
,340126,ED_1b,ED1,411,0.737864078,
,340030,ED_1b,ED1,406,0.721682848,
,340147,ED_1b,ED1,404,0.715210356,
,340061,ED_1b,ED1,397,0.692556634,
,341324,ED_1b,ED1,394,0.682847896,
,340155,ED_1b,ED1,384,0.650485437,
,341315,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,384,1,
,340050,ED_1b,ED1,375,0.621359223,
,340132,ED_1b,ED1,373,0.614886731,
,340004,ED_1b,ED1,364,0.585760518,
,340073,ED_1b,ED1,358,0.566343042,
,340002,ED_1b,ED1,355,0.556634304,
,340069,ED_1b,ED1,351,0.54368932,
,340041,ED_1b,ED1,350,0.540453074,
,340131,ED_1b,ED1,350,0.540453074,
,340114,ED_1b,ED1,345,0.524271845,
,340071,ED_1b,ED1,342,0.514563107,
,340085,ED_1b,ED1,340,0.508090615,
,340008,ED_1b,ED1,338,0.501618123,
,340047,ED_1b,ED1,335,0.491909385,
,340084,ED_1b,ED1,335,0.491909385,
,340173,ED_1b,ED1,328,0.469255663,
,340091,ED_1b,ED1,318,0.436893204,
,340119,ED_1b,ED1,318,0.436893204,
,340090,ED_1b,ED1,313,0.420711974,
,341318,ED_1b,ED1,312,0.417475728,
,340032,ED_1b,ED1,310,0.411003236,
,340014,ED_1b,ED1,308,0.404530744,
,340115,ED_1b,ED1,306,0.398058252,
,340171,ED_1b,ED1,306,0.398058252,
,340113,ED_1b,ED1,304,0.391585761,
,340107,ED_1b,ED1,302,0.385113269,
,340001,ED_1b,ED1,301,0.381877023,
,340142,ED_1b,ED1,301,0.381877023,
,340184,ED_1b,ED1,300,0.378640777,
,340106,ED_1b,ED1,298,0.372168285,
,340024,ED_1b,ED1,297,0.368932039,
,341315,ED_1b,ED1,294,0.359223301,
,340109,ED_1b,ED1,293,0.355987055,
,340127,ED_1b,ED1,293,0.355987055,
,341311,ED_1b,ED1,293,0.355987055,
,340060,ED_1b,ED1,292,0.352750809,
,340130,ED_1b,ED1,291,0.349514563,
,340133,ED_1b,ED1,290,0.346278317,
,340141,ED_1b,ED1,289,0.343042071,
,340116,ED_1b,ED1,288,0.339805825,
,340166,ED_1b,ED1,287,0.336569579,
,340120,ED_1b,ED1,282,0.32038835,
,340068,ED_1b,ED1,281,0.317152104,
,340003,ED_1b,ED1,280,0.313915858,
,340017,ED_1b,ED1,278,0.307443366,
,340070,ED_1b,ED1,277,0.30420712,
,340188,ED_1b,ED1,276,0.300970874,
,340030,OP_18b,OP 18,275,1,
,340151,ED_1b,ED1,272,0.28802589,
,341328,ED_1b,ED1,272,0.28802589,
,340015,ED_1b,ED1,271,0.284789644,
,340097,ED_1b,ED1,271,0.284789644,
,340075,ED_1b,ED1,267,0.27184466,
,340144,ED_1b,ED1,267,0.27184466,
,340020,ED_1b,ED1,266,0.268608414,
,340131,OP_18b,OP 18,265,0.951219512,
,340027,ED_1b,ED1,264,0.262135922,
,340186,ED_1b,ED1,264,0.262135922,
,341326,ED_1b,ED1,263,0.258899676,
,340010,ED_1b,ED1,262,0.25566343,
,340023,ED_1b,ED1,262,0.25566343,
,340099,ED_1b,ED1,262,0.25566343,
,340158,ED_1b,ED1,262,0.25566343,
,340053,ED_1b,ED1,261,0.252427184,
,340013,ED_1b,ED1,258,0.242718447,
,340096,ED_1b,ED1,250,0.216828479,
,340061,ED_2b,ED2,249,1,
,340143,ED_1b,ED1,249,0.213592233,
,340087,ED_1b,ED1,248,0.210355987,
,340098,ED_1b,ED1,246,0.203883495,
,340039,ED_1b,ED1,243,0.194174757,
,341327,ED_1b,ED1,241,0.187702265,
,340051,ED_1b,ED1,240,0.184466019,
,340129,ED_1b,ED1,237,0.174757282,
,340183,ED_1b,ED1,237,0.174757282,
,340123,ED_1b,ED1,234,0.165048544,
,340159,ED_1b,ED1,232,0.158576052,
,340114,ED_2b,ED2,231,0.927710843,
,341316,ED_1b,ED1,231,0.155339806,
,340021,ED_1b,ED1,230,0.15210356,
,340145,ED_1b,ED1,229,0.148867314,
,340042,ED_2b,ED2,228,0.915662651,
,340064,ED_1b,ED1,228,0.145631068,
,340126,ED_2b,ED2,228,0.915662651,
,340156,ED_1b,ED1,228,0.145631068,
,341322,ED_1b,ED1,226,0.139158576,
,340016,ED_1b,ED1,224,0.132686084,
,340040,ED_2b,ED2,223,0.895582329,
,341307,ED_1b,ED1,223,0.129449838,
,340002,OP_18b,OP 18,221,0.736585366,
,340028,ED_2b,ED2,221,0.887550201,
,341325,ED_1b,ED1,221,0.122977346,
,340037,ED_1b,ED1,214,0.100323625,
,341304,ED_1b,ED1,214,0.100323625,
,341329,ED_1b,ED1,212,0.093851133,
,340050,OP_18b,OP 18,208,0.673170732,
,340042,OP_18b,OP 18,207,0.668292683,
,340171,OP_18b,OP 18,206,0.663414634,
,341303,ED_1b,ED1,206,0.074433657,
,340142,OP_18b,OP 18,205,0.658536585,
,341305,ED_1b,ED1,204,0.067961165,
,340040,OP_18b,OP 18,201,0.63902439,
,340061,OP_18b,OP 18,200,0.634146341,
,341319,ED_1b,ED1,200,0.055016181,
,340132,OP_18b,OP 18,193,0.6,
,340041,ED_2b,ED2,192,0.771084337,
,340113,OP_18b,OP 18,192,0.595121951,
,340073,ED_2b,ED2,190,0.763052209,
,340114,OP_18b,OP 18,190,0.585365854,
,340147,ED_2b,ED2,188,0.75502008,
,340107,OP_18b,OP 18,186,0.565853659,
,341320,ED_1b,ED1,183,0,
,340116,OP_18b,OP 18,182,0.546341463,
,340001,OP_18b,OP 18,180,0.536585366,
,340047,OP_18b,OP 18,180,0.536585366,
,340098,OP_18b,OP 18,180,0.536585366,
,340155,ED_2b,ED2,180,0.722891566,
,340070,OP_18b,OP 18,178,0.526829268,
,340173,OP_18b,OP 18,177,0.52195122,
,340147,OP_18b,OP 18,174,0.507317073,
,340155,OP_18b,OP 18,174,0.507317073,
,340091,OP_18b,OP 18,173,0.502439024,
,340119,OP_18b,OP 18,173,0.502439024,
,340017,OP_18b,OP 18,172,0.497560976,
,340028,OP_18b,OP 18,172,0.497560976,
,340085,OP_18b,OP 18,172,0.497560976,
,340123,OP_18b,OP 18,172,0.497560976,
,340183,OP_18b,OP 18,172,0.497560976,
,340008,ED_2b,ED2,171,0.686746988,
,340053,OP_18b,OP 18,168,0.47804878,
,340069,OP_18b,OP 18,168,0.47804878,
,340151,OP_18b,OP 18,168,0.47804878,
,340186,OP_18b,OP 18,168,0.47804878,
,340071,ED_2b,ED2,167,0.670682731,
,340014,OP_18b,OP 18,166,0.468292683,
,340188,OP_18b,OP 18,166,0.468292683,
,341315,OP_18b,OP 18,166,0.468292683,
,341324,OP_18b,OP 18,166,0.468292683,
,340127,OP_18b,OP 18,165,0.463414634,
,340039,OP_18b,OP 18,164,0.458536585,
,340166,OP_18b,OP 18,164,0.458536585,
,340003,OP_18b,OP 18,160,0.43902439,
,340004,OP_18b,OP 18,160,0.43902439,
,340032,OP_18b,OP 18,160,0.43902439,
,340050,ED_2b,ED2,160,0.642570281,
,340090,OP_18b,OP 18,160,0.43902439,
,340120,ED_2b,ED2,159,0.638554217,
,340023,OP_18b,OP 18,158,0.429268293,
,340126,OP_18b,OP 18,158,0.429268293,
,340141,OP_18b,OP 18,158,0.429268293,
,340087,OP_18b,OP 18,157,0.424390244,
,340051,OP_18b,OP 18,156,0.419512195,
,340068,OP_18b,OP 18,156,0.419512195,
,340013,OP_18b,OP 18,154,0.409756098,
,340145,OP_18b,OP 18,154,0.409756098,
,340173,ED_2b,ED2,154,0.618473896,
,341327,OP_18b,OP 18,154,0.409756098,
,340084,OP_18b,OP 18,152,0.4,
,340096,OP_18b,OP 18,152,0.4,
,340097,OP_18b,OP 18,152,0.4,
,340184,OP_18b,OP 18,152,0.4,
,340141,ED_2b,ED2,151,0.606425703,
,340015,OP_18b,OP 18,150,0.390243902,
,340143,OP_18b,OP 18,150,0.390243902,
,341328,OP_18b,OP 18,150,0.390243902,
,341318,OP_18b,OP 18,146,0.370731707,
,340020,OP_18b,OP 18,145,0.365853659,
,340002,ED_2b,ED2,144,0.578313253,
,340132,ED_2b,ED2,144,0.578313253,
,340184,ED_2b,ED2,143,0.574297189,
,340115,OP_18b,OP 18,142,0.351219512,
,340133,OP_18b,OP 18,142,0.351219512,
,340008,OP_18b,OP 18,140,0.341463415,
,340024,OP_18b,OP 18,140,0.341463415,
,340027,OP_18b,OP 18,140,0.341463415,
,340060,OP_18b,OP 18,139,0.336585366,
,340069,ED_2b,ED2,139,0.558232932,
,340130,OP_18b,OP 18,139,0.336585366,
,341325,OP_18b,OP 18,139,0.336585366,
,340010,OP_18b,OP 18,138,0.331707317,
,340041,OP_18b,OP 18,137,0.326829268,
,340064,OP_18b,OP 18,137,0.326829268,
,340158,OP_18b,OP 18,137,0.326829268,
,340071,OP_18b,OP 18,136,0.32195122,
,341326,OP_18b,OP 18,135,0.317073171,
,340073,OP_18b,OP 18,134,0.312195122,
,340075,OP_18b,OP 18,134,0.312195122,
,340144,OP_18b,OP 18,134,0.312195122,
,340115,ED_2b,ED2,130,0.522088353,
,341319,OP_18b,OP 18,130,0.292682927,
,340099,OP_18b,OP 18,128,0.282926829,
,340109,OP_18b,OP 18,128,0.282926829,
,341316,OP_18b,OP 18,124,0.263414634,
,340016,OP_18b,OP 18,122,0.253658537,
,340129,OP_18b,OP 18,122,0.253658537,
,340032,ED_2b,ED2,121,0.485943775,
,340060,ED_2b,ED2,120,0.481927711,
,340116,ED_2b,ED2,120,0.481927711,
,340020,ED_2b,ED2,118,0.473895582,
,340004,ED_2b,ED2,117,0.469879518,
,340021,OP_18b,OP 18,115,0.219512195,
,340068,ED_2b,ED2,115,0.46184739,
,340106,OP_18b,OP 18,115,0.219512195,
,340097,ED_2b,ED2,114,0.457831325,
,341329,OP_18b,OP 18,113,0.209756098,
,340091,ED_2b,ED2,112,0.449799197,
,340159,OP_18b,OP 18,112,0.204878049,
,340013,ED_2b,ED2,111,0.445783133,
,340075,ED_2b,ED2,111,0.445783133,
,340120,OP_18b,OP 18,110,0.195121951,
,340047,ED_2b,ED2,108,0.43373494,
,340119,ED_2b,ED2,107,0.429718876,
,340187,OP_18b,OP 18,106,0.175609756,
,340037,OP_18b,OP 18,104,0.165853659,
,341324,ED_2b,ED2,103,0.413654618,
,340085,ED_2b,ED2,102,0.409638554,
,341304,OP_18b,OP 18,102,0.156097561,
,340001,STK_4,Thrombolytic Therapy,100,1,
,340002,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340003,IMM_2,Immunization for influenza,100,1,
,340003,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340003,OP_4,Aspirin at Arrival,100,1,
,340004,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340004,OP_4,Aspirin at Arrival,100,1,
,340004,VTE_5,Warfarin therapy discharge instructions,100,1,
,340010,VTE_5,Warfarin therapy discharge instructions,100,1,
,340014,IMM_2,Immunization for influenza,100,1,
,340014,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340014,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340014,OP_4,Aspirin at Arrival,100,1,
,340014,VTE_5,Warfarin therapy discharge instructions,100,1,
,340015,IMM_2,Immunization for influenza,100,1,
,340015,OP_4,Aspirin at Arrival,100,1,
,340015,VTE_5,Warfarin therapy discharge instructions,100,1,
,340017,OP_4,Aspirin at Arrival,100,1,
,340021,OP_4,Aspirin at Arrival,100,1,
,340027,OP_4,Aspirin at Arrival,100,1,
,340028,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340028,VTE_5,Warfarin therapy discharge instructions,100,1,
,340030,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340032,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340032,STK_4,Thrombolytic Therapy,100,1,
,340037,VTE_5,Warfarin therapy discharge instructions,100,1,
,340039,VTE_5,Warfarin therapy discharge instructions,100,1,
,340041,IMM_2,Immunization for influenza,100,1,
,340041,VTE_5,Warfarin therapy discharge instructions,100,1,
,340042,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340047,STK_4,Thrombolytic Therapy,100,1,
,340047,VTE_5,Warfarin therapy discharge instructions,100,1,
,340049,IMM_2,Immunization for influenza,100,1,
,340050,OP_4,Aspirin at Arrival,100,1,
,340051,OP_4,Aspirin at Arrival,100,1,
,340051,VTE_5,Warfarin therapy discharge instructions,100,1,
,340053,STK_4,Thrombolytic Therapy,100,1,
,340053,VTE_5,Warfarin therapy discharge instructions,100,1,
,340060,IMM_2,Immunization for influenza,100,1,
,340061,STK_4,Thrombolytic Therapy,100,1,
,340061,VTE_5,Warfarin therapy discharge instructions,100,1,
,340064,OP_4,Aspirin at Arrival,100,1,
,340068,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,340068,OP_4,Aspirin at Arrival,100,1,
,340069,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,340069,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340070,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340070,OP_4,Aspirin at Arrival,100,1,
,340071,OP_4,Aspirin at Arrival,100,1,
,340071,VTE_5,Warfarin therapy discharge instructions,100,1,
,340073,IMM_2,Immunization for influenza,100,1,
,340073,VTE_5,Warfarin therapy discharge instructions,100,1,
,340075,VTE_5,Warfarin therapy discharge instructions,100,1,
,340085,IMM_2,Immunization for influenza,100,1,
,340085,OP_23,Head CT results,100,1,
,340085,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340085,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340085,OP_4,Aspirin at Arrival,100,1,
,340087,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340090,OP_4,Aspirin at Arrival,100,1,
,340091,OP_4,Aspirin at Arrival,100,1,
,340096,IMM_2,Immunization for influenza,100,1,
,340096,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340097,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,340097,STK_4,Thrombolytic Therapy,100,1,
,340097,VTE_5,Warfarin therapy discharge instructions,100,1,
,340099,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,340106,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340106,OP_4,Aspirin at Arrival,100,1,
,340107,OP_4,Aspirin at Arrival,100,1,
,340107,VTE_5,Warfarin therapy discharge instructions,100,1,
,340109,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340113,ED_2b,ED2,100,0.401606426,
,340114,STK_4,Thrombolytic Therapy,100,1,
,340115,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,340115,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340115,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340115,STK_4,Thrombolytic Therapy,100,1,
,340116,STK_4,Thrombolytic Therapy,100,1,
,340116,VTE_5,Warfarin therapy discharge instructions,100,1,
,340120,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340126,VTE_5,Warfarin therapy discharge instructions,100,1,
,340127,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340127,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340129,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340129,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340130,STK_4,Thrombolytic Therapy,100,1,
,340131,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340131,VTE_5,Warfarin therapy discharge instructions,100,1,
,340133,OP_4,Aspirin at Arrival,100,1,
,340142,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340142,VTE_5,Warfarin therapy discharge instructions,100,1,
,340143,VTE_5,Warfarin therapy discharge instructions,100,1,
,340144,IMM_2,Immunization for influenza,100,1,
,340144,OP_4,Aspirin at Arrival,100,1,
,340148,IMM_2,Immunization for influenza,100,1,
,340151,OP_23,Head CT results,100,1,
,340151,VTE_5,Warfarin therapy discharge instructions,100,1,
,340155,VTE_5,Warfarin therapy discharge instructions,100,1,
,340158,OP_23,Head CT results,100,1,
,340158,OP_4,Aspirin at Arrival,100,1,
,340159,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340166,VTE_5,Warfarin therapy discharge instructions,100,1,
,340171,VTE_5,Warfarin therapy discharge instructions,100,1,
,340173,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340173,VTE_5,Warfarin therapy discharge instructions,100,1,
,340183,IMM_2,Immunization for influenza,100,1,
,340183,OP_4,Aspirin at Arrival,100,1,
,340183,VTE_5,Warfarin therapy discharge instructions,100,1,
,340184,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,100,1,
,340184,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,340184,VTE_5,Warfarin therapy discharge instructions,100,1,
,340186,IMM_2,Immunization for influenza,100,1,
,341303,OP_4,Aspirin at Arrival,100,1,
,341304,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,341315,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,100,1,
,341318,IMM_2,Immunization for influenza,100,1,
,341318,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,341319,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,341320,OP_4,Aspirin at Arrival,100,1,
,341325,OP_4,Aspirin at Arrival,100,1,
,341326,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,341329,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,100,1,
,341329,OP_4,Aspirin at Arrival,100,1,
,340001,VTE_5,Warfarin therapy discharge instructions,99,0.97826087,
,340003,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,340008,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340013,OP_4,Aspirin at Arrival,99,0.96875,
,340014,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340015,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,340017,IMM_2,Immunization for influenza,99,0.941176471,
,340020,OP_4,Aspirin at Arrival,99,0.96875,
,340021,IMM_2,Immunization for influenza,99,0.941176471,
,340028,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340030,ED_2b,ED2,99,0.397590361,
,340030,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340032,IMM_2,Immunization for influenza,99,0.941176471,
,340037,IMM_2,Immunization for influenza,99,0.941176471,
,340037,OP_4,Aspirin at Arrival,99,0.96875,
,340040,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340041,OP_4,Aspirin at Arrival,99,0.96875,
,340050,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340051,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,0.986486486,
,340053,IMM_2,Immunization for influenza,99,0.941176471,
,340060,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340061,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,0.986486486,
,340064,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,340069,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,340071,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340075,IMM_2,Immunization for influenza,99,0.941176471,
,340087,OP_4,Aspirin at Arrival,99,0.96875,
,340090,IMM_2,Immunization for influenza,99,0.941176471,
,340099,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,0.986486486,
,340107,IMM_2,Immunization for influenza,99,0.941176471,
,340107,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340114,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340120,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,340123,IMM_2,Immunization for influenza,99,0.941176471,
,340123,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340126,IMM_2,Immunization for influenza,99,0.941176471,
,340127,OP_4,Aspirin at Arrival,99,0.96875,
,340129,IMM_2,Immunization for influenza,99,0.941176471,
,340130,ED_2b,ED2,99,0.397590361,
,340131,ED_2b,ED2,99,0.397590361,
,340131,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340132,IMM_2,Immunization for influenza,99,0.941176471,
,340132,OP_4,Aspirin at Arrival,99,0.96875,
,340133,IMM_2,Immunization for influenza,99,0.941176471,
,340141,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340142,OP_4,Aspirin at Arrival,99,0.96875,
,340143,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340145,OP_4,Aspirin at Arrival,99,0.96875,
,340151,OP_4,Aspirin at Arrival,99,0.96875,
,340155,IMM_2,Immunization for influenza,99,0.941176471,
,340155,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340158,IMM_2,Immunization for influenza,99,0.941176471,
,340159,OP_4,Aspirin at Arrival,99,0.96875,
,340171,IMM_2,Immunization for influenza,99,0.941176471,
,340173,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340184,IMM_2,Immunization for influenza,99,0.941176471,
,340184,OP_4,Aspirin at Arrival,99,0.96875,
,340186,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,340186,OP_4,Aspirin at Arrival,99,0.96875,
,341304,IMM_2,Immunization for influenza,99,0.941176471,
,341305,IMM_2,Immunization for influenza,99,0.941176471,
,341318,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,99,0.98,
,341318,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,341318,OP_4,Aspirin at Arrival,99,0.96875,
,341324,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,99,0.986486486,
,341328,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,99,0.989010989,
,341328,OP_4,Aspirin at Arrival,99,0.96875,
,340004,IMM_2,Immunization for influenza,98,0.882352941,
,340008,OP_4,Aspirin at Arrival,98,0.9375,
,340010,IMM_2,Immunization for influenza,98,0.882352941,
,340010,OP_4,Aspirin at Arrival,98,0.9375,
,340015,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340015,OP_23,Head CT results,98,0.98,
,340023,OP_4,Aspirin at Arrival,98,0.9375,
,340028,IMM_2,Immunization for influenza,98,0.882352941,
,340030,VTE_5,Warfarin therapy discharge instructions,98,0.956521739,
,340039,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340039,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,98,0.978021978,
,340047,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,0.972972973,
,340049,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340051,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340061,IMM_2,Immunization for influenza,98,0.882352941,
,340064,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,0.972972973,
,340068,IMM_2,Immunization for influenza,98,0.882352941,
,340069,IMM_2,Immunization for influenza,98,0.882352941,
,340069,VTE_5,Warfarin therapy discharge instructions,98,0.956521739,
,340073,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340085,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340090,ED_2b,ED2,98,0.393574297,
,340090,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,0.972972973,
,340096,OP_4,Aspirin at Arrival,98,0.9375,
,340097,OP_4,Aspirin at Arrival,98,0.9375,
,340098,IMM_2,Immunization for influenza,98,0.882352941,
,340098,VTE_5,Warfarin therapy discharge instructions,98,0.956521739,
,340114,IMM_2,Immunization for influenza,98,0.882352941,
,340114,VTE_5,Warfarin therapy discharge instructions,98,0.956521739,
,340115,IMM_2,Immunization for influenza,98,0.882352941,
,340116,IMM_2,Immunization for influenza,98,0.882352941,
,340119,IMM_2,Immunization for influenza,98,0.882352941,
,340120,OP_4,Aspirin at Arrival,98,0.9375,
,340126,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340127,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340130,IMM_2,Immunization for influenza,98,0.882352941,
,340132,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,0.972972973,
,340148,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340151,IMM_2,Immunization for influenza,98,0.882352941,
,340151,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340158,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340159,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,340159,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,98,0.972972973,
,340173,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,98,0.978021978,
,340183,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,341303,IMM_2,Immunization for influenza,98,0.882352941,
,341303,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,341304,OP_4,Aspirin at Arrival,98,0.9375,
,341319,OP_4,Aspirin at Arrival,98,0.9375,
,341322,IMM_2,Immunization for influenza,98,0.882352941,
,341323,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,341324,OP_4,Aspirin at Arrival,98,0.9375,
,341326,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,98,0.96,
,341326,OP_4,Aspirin at Arrival,98,0.9375,
,340001,IMM_2,Immunization for influenza,97,0.823529412,
,340004,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340014,STK_4,Thrombolytic Therapy,97,0.931818182,
,340016,IMM_2,Immunization for influenza,97,0.823529412,
,340020,IMM_2,Immunization for influenza,97,0.823529412,
,340030,IMM_2,Immunization for influenza,97,0.823529412,
,340032,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340050,IMM_2,Immunization for influenza,97,0.823529412,
,340061,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340084,IMM_2,Immunization for influenza,97,0.823529412,
,340090,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,0.967032967,
,340091,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340097,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340098,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340099,IMM_2,Immunization for influenza,97,0.823529412,
,340099,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,0.967032967,
,340113,IMM_2,Immunization for influenza,97,0.823529412,
,340113,STK_4,Thrombolytic Therapy,97,0.931818182,
,340119,OP_4,Aspirin at Arrival,97,0.90625,
,340120,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340123,OP_4,Aspirin at Arrival,97,0.90625,
,340130,OP_4,Aspirin at Arrival,97,0.90625,
,340131,IMM_2,Immunization for influenza,97,0.823529412,
,340132,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,97,0.967032967,
,340143,OP_4,Aspirin at Arrival,97,0.90625,
,340147,OP_4,Aspirin at Arrival,97,0.90625,
,340147,VTE_5,Warfarin therapy discharge instructions,97,0.934782609,
,340155,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340156,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340158,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340166,IMM_2,Immunization for influenza,97,0.823529412,
,340166,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,340171,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,340186,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,97,0.959459459,
,341311,IMM_2,Immunization for influenza,97,0.823529412,
,341315,OP_4,Aspirin at Arrival,97,0.90625,
,341324,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,97,0.94,
,341326,IMM_2,Immunization for influenza,97,0.823529412,
,341329,IMM_2,Immunization for influenza,97,0.823529412,
,340001,OP_4,Aspirin at Arrival,96,0.875,
,340002,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340008,IMM_2,Immunization for influenza,96,0.764705882,
,340013,IMM_2,Immunization for influenza,96,0.764705882,
,340020,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340021,VTE_5,Warfarin therapy discharge instructions,96,0.913043478,
,340024,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340027,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340032,VTE_5,Warfarin therapy discharge instructions,96,0.913043478,
,340039,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,0.945945946,
,340040,IMM_2,Immunization for influenza,96,0.764705882,
,340040,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,0.945945946,
,340042,IMM_2,Immunization for influenza,96,0.764705882,
,340053,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340069,STK_4,Thrombolytic Therapy,96,0.909090909,
,340070,ED_2b,ED2,96,0.385542169,
,340070,IMM_2,Immunization for influenza,96,0.764705882,
,340070,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340084,OP_4,Aspirin at Arrival,96,0.875,
,340098,OP_4,Aspirin at Arrival,96,0.875,
,340106,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,0.945945946,
,340109,IMM_2,Immunization for influenza,96,0.764705882,
,340113,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,0.945945946,
,340119,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340126,OP_4,Aspirin at Arrival,96,0.875,
,340129,OP_4,Aspirin at Arrival,96,0.875,
,340132,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,96,0.92,
,340133,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,96,0.945945946,
,340143,IMM_2,Immunization for influenza,96,0.764705882,
,340145,IMM_2,Immunization for influenza,96,0.764705882,
,340147,IMM_2,Immunization for influenza,96,0.764705882,
,340155,STK_4,Thrombolytic Therapy,96,0.909090909,
,340173,IMM_2,Immunization for influenza,96,0.764705882,
,340173,OP_23,Head CT results,96,0.96,
,340186,ED_2b,ED2,96,0.385542169,
,341315,IMM_2,Immunization for influenza,96,0.764705882,
,341316,OP_4,Aspirin at Arrival,96,0.875,
,341324,IMM_2,Immunization for influenza,96,0.764705882,
,341324,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,96,0.956043956,
,341325,IMM_2,Immunization for influenza,96,0.764705882,
,341327,OP_4,Aspirin at Arrival,96,0.875,
,341328,IMM_2,Immunization for influenza,96,0.764705882,
,340002,IMM_2,Immunization for influenza,95,0.705882353,
,340002,STK_4,Thrombolytic Therapy,95,0.886363636,
,340003,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340004,STK_4,Thrombolytic Therapy,95,0.886363636,
,340010,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340017,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,0.945054945,
,340020,OP_23,Head CT results,95,0.95,
,340021,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,0.945054945,
,340023,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340027,IMM_2,Immunization for influenza,95,0.705882353,
,340027,OP_23,Head CT results,95,0.95,
,340032,OP_4,Aspirin at Arrival,95,0.84375,
,340041,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340060,OP_4,Aspirin at Arrival,95,0.84375,
,340064,IMM_2,Immunization for influenza,95,0.705882353,
,340075,OP_4,Aspirin at Arrival,95,0.84375,
,340091,IMM_2,Immunization for influenza,95,0.705882353,
,340096,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340099,OP_4,Aspirin at Arrival,95,0.84375,
,340106,IMM_2,Immunization for influenza,95,0.705882353,
,340120,IMM_2,Immunization for influenza,95,0.705882353,
,340126,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,0.932432432,
,340144,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,0.945054945,
,340147,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,340166,OP_4,Aspirin at Arrival,95,0.84375,
,340171,OP_4,Aspirin at Arrival,95,0.84375,
,340173,OP_4,Aspirin at Arrival,95,0.84375,
,340188,IMM_2,Immunization for influenza,95,0.705882353,
,341304,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,95,0.945054945,
,341304,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,0.932432432,
,341316,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,95,0.9,
,341328,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,95,0.932432432,
,340016,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,94,0.88,
,340027,ED_2b,ED2,94,0.37751004,
,340027,VTE_5,Warfarin therapy discharge instructions,94,0.869565217,
,340039,OP_4,Aspirin at Arrival,94,0.8125,
,340042,OP_4,Aspirin at Arrival,94,0.8125,
,340051,IMM_2,Immunization for influenza,94,0.647058824,
,340061,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,0.934065934,
,340069,OP_4,Aspirin at Arrival,94,0.8125,
,340071,IMM_2,Immunization for influenza,94,0.647058824,
,340073,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,0.934065934,
,340087,IMM_2,Immunization for influenza,94,0.647058824,
,340097,OP_23,Head CT results,94,0.94,
,340109,OP_4,Aspirin at Arrival,94,0.8125,
,340131,OP_21,Median time to pain med,94,1,
,340145,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,94,0.918918919,
,340147,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,0.934065934,
,340158,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,94,0.934065934,
,340171,ED_2b,ED2,94,0.37751004,
,341318,ED_2b,ED2,94,0.37751004,
,340004,OP_21,Median time to pain med,93,0.986842105,
,340016,OP_4,Aspirin at Arrival,93,0.78125,
,340017,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,0.905405405,
,340028,STK_4,Thrombolytic Therapy,93,0.840909091,
,340030,STK_4,Thrombolytic Therapy,93,0.840909091,
,340039,IMM_2,Immunization for influenza,93,0.588235294,
,340042,VTE_5,Warfarin therapy discharge instructions,93,0.847826087,
,340051,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,0.923076923,
,340068,OP_23,Head CT results,93,0.93,
,340084,ED_2b,ED2,93,0.373493976,
,340084,OP_21,Median time to pain med,93,0.986842105,
,340087,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,0.86,
,340091,VTE_5,Warfarin therapy discharge instructions,93,0.847826087,
,340097,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,0.923076923,
,340113,OP_4,Aspirin at Arrival,93,0.78125,
,340113,VTE_5,Warfarin therapy discharge instructions,93,0.847826087,
,340115,VTE_5,Warfarin therapy discharge instructions,93,0.847826087,
,340119,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,0.905405405,
,340141,STK_4,Thrombolytic Therapy,93,0.840909091,
,340142,IMM_2,Immunization for influenza,93,0.588235294,
,340151,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,93,0.905405405,
,340155,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,0.923076923,
,340186,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,93,0.923076923,
,340187,OP_4,Aspirin at Arrival,93,0.78125,
,341319,IMM_2,Immunization for influenza,93,0.588235294,
,341319,VTE_5,Warfarin therapy discharge instructions,93,0.847826087,
,341328,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,0.86,
,341329,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,93,0.86,
,340002,VTE_5,Warfarin therapy discharge instructions,92,0.826086957,
,340008,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,0.912087912,
,340016,ED_2b,ED2,92,0.369477912,
,340021,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,0.891891892,
,340047,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,0.912087912,
,340084,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,92,0.84,
,340091,STK_4,Thrombolytic Therapy,92,0.818181818,
,340099,VTE_5,Warfarin therapy discharge instructions,92,0.826086957,
,340107,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,92,0.912087912,
,340115,OP_4,Aspirin at Arrival,92,0.75,
,340116,OP_23,Head CT results,92,0.92,
,340116,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,0.891891892,
,340127,IMM_2,Immunization for influenza,92,0.529411765,
,340130,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,0.891891892,
,340183,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,92,0.891891892,
,340001,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340001,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,91,0.878378378,
,340016,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,91,0.901098901,
,340017,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340021,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340032,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340042,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340047,IMM_2,Immunization for influenza,91,0.470588235,
,340069,OP_23,Head CT results,91,0.91,
,340090,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340090,VTE_5,Warfarin therapy discharge instructions,91,0.804347826,
,340091,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,91,0.878378378,
,340107,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,91,1,
,340109,ED_2b,ED2,91,0.365461847,
,340127,OP_21,Median time to pain med,91,0.960526316,
,340158,ED_2b,ED2,91,0.365461847,
,340159,IMM_2,Immunization for influenza,91,0.470588235,
,340187,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,341319,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,91,0.82,
,340003,OP_23,Head CT results,90,0.9,
,340060,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,90,0.864864865,
,340070,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,0.89010989,
,340097,IMM_2,Immunization for influenza,90,0.411764706,
,340113,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,0.89010989,
,340127,ED_2b,ED2,90,0.361445783,
,340141,IMM_2,Immunization for influenza,90,0.411764706,
,340145,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,90,0.8,
,340155,OP_4,Aspirin at Arrival,90,0.6875,
,340166,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,90,0.89010989,
,340171,OP_23,Head CT results,90,0.9,
,340188,OP_4,Aspirin at Arrival,90,0.6875,
,341305,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,90,0.8,
,341323,IMM_2,Immunization for influenza,90,0.411764706,
,340010,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,0.851351351,
,340023,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,0.851351351,
,340024,OP_4,Aspirin at Arrival,89,0.65625,
,340032,OP_23,Head CT results,89,0.89,
,340047,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,89,0.78,
,340113,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,89,0.78,
,340119,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,0.879120879,
,340119,VTE_5,Warfarin therapy discharge instructions,89,0.760869565,
,340143,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,89,0.851351351,
,340145,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,0.879120879,
,341304,ED_2b,ED2,89,0.357429719,
,341326,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,89,0.879120879,
,340001,ED_2b,ED2,88,0.353413655,
,340003,ED_2b,ED2,88,0.353413655,
,340015,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,88,0.837837838,
,340030,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,0.868131868,
,340040,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,0.868131868,
,340053,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,88,0.868131868,
,340090,OP_23,Head CT results,88,0.88,
,340126,OP_23,Head CT results,88,0.88,
,340133,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,88,0.76,
,340141,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,88,0.837837838,
,340016,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,87,0.824324324,
,340024,IMM_2,Immunization for influenza,87,0.235294118,
,340037,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,87,0.74,
,340109,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,87,0.74,
,340156,IMM_2,Immunization for influenza,87,0.235294118,
,340008,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,86,0.810810811,
,340023,IMM_2,Immunization for influenza,86,0.176470588,
,340098,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,86,0.846153846,
,340107,ED_2b,ED2,86,0.345381526,
,340129,VTE_5,Warfarin therapy discharge instructions,86,0.695652174,
,340141,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,86,0.846153846,
,340166,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,86,0.72,
,340171,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,86,0.810810811,
,341311,ED_2b,ED2,86,0.345381526,
,341315,OP_21,Median time to pain med,86,0.894736842,
,340013,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,0.7,
,340023,ED_2b,ED2,85,0.341365462,
,340040,VTE_5,Warfarin therapy discharge instructions,85,0.673913043,
,340075,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,0.7,
,340096,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,85,0.835164835,
,340120,OP_23,Head CT results,85,0.85,
,340142,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,0.7,
,340151,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,85,0.835164835,
,340184,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,85,0.7,
,341317,IMM_2,Immunization for influenza,85,0.117647059,
,340001,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,0.824175824,
,340017,VTE_5,Warfarin therapy discharge instructions,84,0.652173913,
,340041,OP_21,Median time to pain med,84,0.868421053,
,340041,OP_23,Head CT results,84,0.84,
,340126,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,0.824175824,
,340147,OP_23,Head CT results,84,0.84,
,340151,ED_2b,ED2,84,0.337349398,
,341319,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,84,0.824175824,
,340002,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,83,0.813186813,
,340040,STK_4,Thrombolytic Therapy,83,0.613636364,
,340071,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,83,0.813186813,
,340073,OP_21,Median time to pain med,83,0.855263158,
,340099,ED_2b,ED2,83,0.333333333,
,340116,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,0.66,
,340123,VTE_5,Warfarin therapy discharge instructions,83,0.630434783,
,340130,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,0.66,
,341316,IMM_2,Immunization for influenza,83,0,
,341322,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,83,0.66,
,341326,OP_23,Head CT results,83,0.83,
,340010,OP_23,Head CT results,82,0.82,
,340014,ED_2b,ED2,82,0.329317269,
,340015,ED_2b,ED2,82,0.329317269,
,340039,ED_2b,ED2,82,0.329317269,
,340064,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,82,0.64,
,340123,ED_2b,ED2,82,0.329317269,
,340127,OP_23,Head CT results,82,0.82,
,340129,OP_23,Head CT results,82,0.82,
,340131,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,82,0.802197802,
,340133,OP_23,Head CT results,82,0.82,
,340142,OP_23,Head CT results,82,0.82,
,340155,OP_23,Head CT results,82,0.82,
,340042,OP_23,Head CT results,81,0.81,
,340114,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,81,0.791208791,
,340133,ED_2b,ED2,81,0.325301205,
,340010,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,80,0.830769231,
,340021,ED_2b,ED2,80,0.321285141,
,340053,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,80,0.72972973,
,340060,OP_21,Median time to pain med,80,0.815789474,
,340091,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,80,0.78021978,
,340098,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,80,0.6,
,340183,OP_23,Head CT results,80,0.8,
,341303,OP_18b,OP 18,80,0.048780488,
,341320,OP_18b,OP 18,80,0.048780488,
,340041,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,79,0.716216216,
,340050,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,79,0.716216216,
,340106,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,79,0.58,
,341319,OP_23,Head CT results,79,0.79,
,340010,ED_2b,ED2,78,0.313253012,
,340013,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,78,0.702702703,
,340024,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,78,0.758241758,
,340039,OP_23,Head CT results,78,0.78,
,340053,ED_2b,ED2,78,0.313253012,
,340068,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,78,0.702702703,
,340106,ED_2b,ED2,78,0.313253012,
,340107,OP_21,Median time to pain med,78,0.789473684,
,340143,OP_21,Median time to pain med,78,0.789473684,
,340144,ED_2b,ED2,78,0.313253012,
,340064,OP_23,Head CT results,77,0.77,
,340114,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,77,0.689189189,
,340126,STK_4,Thrombolytic Therapy,77,0.477272727,
,340188,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,77,0.54,
,340010,OP_21,Median time to pain med,76,0.763157895,
,340071,OP_23,Head CT results,76,0.76,
,341307,ED_2b,ED2,76,0.305220884,
,340013,OP_23,Head CT results,75,0.75,
,340030,OP_21,Median time to pain med,75,0.75,
,340073,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,75,0.662162162,
,340087,OP_23,Head CT results,75,0.75,
,340129,ED_2b,ED2,75,0.301204819,
,340166,ED_2b,ED2,75,0.301204819,
,340186,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,75,0.753846154,
,341315,OP_20,Door to diagnostic eval,75,1,
,341328,ED_2b,ED2,75,0.301204819,
,340023,OP_21,Median time to pain med,74,0.736842105,
,340024,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,74,0.648648649,
,340132,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,74,0.124293785,
,341326,ED_2b,ED2,74,0.297188755,
,341327,ED_2b,ED2,74,0.297188755,
,340024,OP_21,Median time to pain med,73,0.723684211,
,340042,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,73,0.703296703,
,340050,VTE_5,Warfarin therapy discharge instructions,72,0.391304348,
,340060,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,72,0.692307692,
,340116,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,72,0.692307692,
,340141,VTE_5,Warfarin therapy discharge instructions,72,0.391304348,
,340017,ED_2b,ED2,71,0.285140562,
,340115,OP_23,Head CT results,71,0.71,
,340119,OP_23,Head CT results,71,0.71,
,341329,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,71,0.681318681,
,340008,OP_21,Median time to pain med,70,0.684210526,
,340071,OP_21,Median time to pain med,70,0.684210526,
,340129,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,70,0.4,
,340142,OP_21,Median time to pain med,70,0.684210526,
,341314,OP_18b,OP 18,70,0,
,340013,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,69,0.661538462,
,340060,OP_23,Head CT results,69,0.69,
,340132,VTE_5,Warfarin therapy discharge instructions,69,0.326086957,
,340151,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,69,0.661538462,
,340008,OP_20,Door to diagnostic eval,68,0.892307692,
,340037,OP_21,Median time to pain med,68,0.657894737,
,340073,OP_4,Aspirin at Arrival,68,0,
,340132,OP_21,Median time to pain med,68,0.657894737,
,340132,OP_23,Head CT results,68,0.68,
,340144,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,68,0.36,
,340171,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,68,0.648351648,
,340188,OP_21,Median time to pain med,68,0.657894737,
,340087,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,67,0.637362637,
,340096,OP_21,Median time to pain med,67,0.644736842,
,340099,OP_23,Head CT results,67,0.67,
,340141,OP_23,Head CT results,67,0.67,
,340188,ED_2b,ED2,67,0.269076305,
,341318,OP_23,Head CT results,67,0.67,
,341328,OP_21,Median time to pain med,67,0.644736842,
,340010,OP_20,Door to diagnostic eval,66,0.861538462,
,340070,OP_21,Median time to pain med,66,0.631578947,
,340075,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,66,0.540540541,
,340096,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,66,0.101694915,
,340130,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,66,0.626373626,
,340027,OP_21,Median time to pain med,65,0.618421053,
,340050,OP_21,Median time to pain med,65,0.618421053,
,340142,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,65,0.615384615,
,340159,ED_2b,ED2,65,0.261044177,
,340004,OP_20,Door to diagnostic eval,64,0.830769231,
,340021,OP_23,Head CT results,64,0.64,
,340023,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,64,0.604395604,
,340115,OP_21,Median time to pain med,64,0.605263158,
,340116,OP_21,Median time to pain med,64,0.605263158,
,340166,OP_23,Head CT results,64,0.64,
,340001,OP_23,Head CT results,63,0.63,
,340028,OP_23,Head CT results,63,0.63,
,340061,OP_21,Median time to pain med,63,0.592105263,
,340142,ED_2b,ED2,63,0.253012048,
,340144,OP_21,Median time to pain med,63,0.592105263,
,340147,OP_21,Median time to pain med,63,0.592105263,
,340147,STK_4,Thrombolytic Therapy,63,0.159090909,
,340173,OP_21,Median time to pain med,63,0.592105263,
,340001,OP_21,Median time to pain med,62,0.578947368,
,340032,OP_21,Median time to pain med,62,0.578947368,
,340037,ED_2b,ED2,62,0.248995984,
,340075,OP_21,Median time to pain med,62,0.578947368,
,340123,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,62,0.486486486,
,340130,OP_21,Median time to pain med,62,0.578947368,
,341305,ED_2b,ED2,62,0.248995984,
,341315,OP_23,Head CT results,62,0.62,
,341324,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,62,0.553846154,
,340109,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,61,0.538461538,
,340123,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,61,0.571428571,
,340126,OP_21,Median time to pain med,61,0.565789474,
,340183,ED_2b,ED2,61,0.24497992,
,340184,OP_21,Median time to pain med,61,0.565789474,
,340002,OP_21,Median time to pain med,60,0.552631579,
,340096,ED_2b,ED2,60,0.240963855,
,340096,OP_23,Head CT results,60,0.6,
,340141,OP_21,Median time to pain med,60,0.552631579,
,340147,OP_20,Door to diagnostic eval,60,0.769230769,
,341320,ED_2b,ED2,60,0.240963855,
,340028,OP_21,Median time to pain med,59,0.539473684,
,340091,OP_23,Head CT results,59,0.59,
,340113,OP_21,Median time to pain med,59,0.539473684,
,340119,OP_21,Median time to pain med,59,0.539473684,
,340123,OP_23,Head CT results,59,0.59,
,340051,OP_21,Median time to pain med,58,0.526315789,
,340133,OP_21,Median time to pain med,58,0.526315789,
,340166,OP_21,Median time to pain med,58,0.526315789,
,341303,ED_2b,ED2,58,0.232931727,
,340010,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,57,0.527472527,
,340039,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,57,0.076271186,
,340068,OP_21,Median time to pain med,57,0.513157895,
,340075,OP_23,Head CT results,57,0.57,
,340084,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,57,0.076271186,
,340087,ED_2b,ED2,57,0.228915663,
,340133,OP_20,Door to diagnostic eval,57,0.723076923,
,340003,OP_21,Median time to pain med,56,0.5,
,340039,OP_21,Median time to pain med,56,0.5,
,340050,STK_4,Thrombolytic Therapy,56,0,
,340145,ED_2b,ED2,56,0.224899598,
,340151,OP_21,Median time to pain med,56,0.5,
,340002,OP_23,Head CT results,55,0.55,
,340070,OP_20,Door to diagnostic eval,55,0.692307692,
,340087,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,55,0.070621469,
,340123,OP_21,Median time to pain med,55,0.486842105,
,340155,OP_21,Median time to pain med,55,0.486842105,
,340183,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,55,0.505494505,
,341329,ED_2b,ED2,55,0.220883534,
,340020,OP_21,Median time to pain med,54,0.473684211,
,340051,ED_2b,ED2,54,0.21686747,
,340109,VTE_5,Warfarin therapy discharge instructions,54,0,
,340131,OP_23,Head CT results,54,0.54,
,340151,OP_20,Door to diagnostic eval,54,0.676923077,
,340069,OP_21,Median time to pain med,53,0.460526316,
,340129,OP_21,Median time to pain med,53,0.460526316,
,341318,OP_21,Median time to pain med,53,0.460526316,
,341319,ED_2b,ED2,53,0.212851406,
,341324,OP_23,Head CT results,53,0.53,
,340024,ED_2b,ED2,52,0.208835341,
,340075,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,52,0.472527473,
,340145,OP_20,Door to diagnostic eval,52,0.646153846,
,340147,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,52,0.4,
,341327,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,52,0.062146893,
,340017,OP_21,Median time to pain med,51,0.434210526,
,340106,OP_21,Median time to pain med,51,0.434210526,
,340120,OP_21,Median time to pain med,51,0.434210526,
,340143,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,51,0.461538462,
,340050,OP_23,Head CT results,50,0.5,
,340156,ED_2b,ED2,50,0.200803213,
,340186,OP_23,Head CT results,50,0.5,
,341317,IMM_3_OP_27_FAC_ADHPCT,Healthcare workers given influenza vaccination,50,0,
,341326,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,50,0.056497175,
,340013,OP_21,Median time to pain med,49,0.407894737,
,340050,OP_20,Door to diagnostic eval,49,0.6,
,340098,ED_2b,ED2,49,0.196787149,
,340130,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,49,0.053672316,
,341316,OP_21,Median time to pain med,49,0.407894737,
,340024,OP_23,Head CT results,48,0.48,
,340039,OP_20,Door to diagnostic eval,48,0.584615385,
,340042,OP_21,Median time to pain med,48,0.394736842,
,340097,OP_21,Median time to pain med,48,0.394736842,
,340158,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,48,0.050847458,
,341303,OP_21,Median time to pain med,48,0.394736842,
,341316,ED_2b,ED2,48,0.192771084,
,340016,OP_21,Median time to pain med,47,0.381578947,
,340021,OP_21,Median time to pain med,47,0.381578947,
,340042,OP_20,Door to diagnostic eval,47,0.569230769,
,340090,OP_21,Median time to pain med,47,0.381578947,
,340119,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,47,0.048022599,
,340143,ED_2b,ED2,47,0.18875502,
,340188,OP_20,Door to diagnostic eval,47,0.569230769,
,340017,OP_20,Door to diagnostic eval,46,0.553846154,
,340023,OP_20,Door to diagnostic eval,46,0.553846154,
,340041,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,46,0.04519774,
,340131,OP_20,Door to diagnostic eval,46,0.553846154,
,341320,OP_21,Median time to pain med,46,0.368421053,
,340114,OP_23,Head CT results,45,0.45,
,341325,ED_2b,ED2,45,0.180722892,
,341326,OP_21,Median time to pain med,45,0.355263158,
,340041,OP_20,Door to diagnostic eval,44,0.523076923,
,340064,ED_2b,ED2,44,0.176706827,
,340091,OP_21,Median time to pain med,44,0.342105263,
,340144,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,44,0.243243243,
,341304,OP_21,Median time to pain med,44,0.342105263,
,341319,OP_21,Median time to pain med,44,0.342105263,
,341327,OP_21,Median time to pain med,44,0.342105263,
,340040,OP_20,Door to diagnostic eval,43,0.507692308,
,340098,OP_23,Head CT results,43,0.43,
,340109,OP_21,Median time to pain med,43,0.328947368,
,340171,OP_20,Door to diagnostic eval,43,0.507692308,
,341322,ED_2b,ED2,43,0.172690763,
,340017,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,42,0.033898305,
,340021,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,42,0.033898305,
,340053,OP_20,Door to diagnostic eval,42,0.492307692,
,340087,OP_21,Median time to pain med,42,0.315789474,
,340098,OP_20,Door to diagnostic eval,42,0.492307692,
,340098,OP_21,Median time to pain med,42,0.315789474,
,340099,OP_21,Median time to pain med,42,0.315789474,
,340114,OP_21,Median time to pain med,42,0.315789474,
,340186,OP_21,Median time to pain med,42,0.315789474,
,341324,OP_21,Median time to pain med,42,0.315789474,
,340142,OP_1,Median Time to Fibrinolysis,41,1,
,340145,OP_21,Median time to pain med,41,0.302631579,
,340003,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,40,0.028248588,
,340145,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,40,0.028248588,
,340123,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,39,0.025423729,
,340166,OP_20,Door to diagnostic eval,39,0.446153846,
,340173,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,39,0.025423729,
,340064,OP_21,Median time to pain med,38,0.263157895,
,340069,OP_20,Door to diagnostic eval,38,0.430769231,
,340090,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,38,0.02259887,
,340113,OP_20,Door to diagnostic eval,38,0.430769231,
,340130,OP_23,Head CT results,38,0.38,
,340183,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,38,0.02259887,
,340187,OP_21,Median time to pain med,38,0.263157895,
,341329,OP_21,Median time to pain med,38,0.263157895,
,340166,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,37,0.019774011,
,340002,OP_20,Door to diagnostic eval,36,0.4,
,340075,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,36,0.016949153,
,340126,OP_1,Median Time to Fibrinolysis,36,0.8,
,340155,OP_20,Door to diagnostic eval,36,0.4,
,341328,OP_20,Door to diagnostic eval,36,0.4,
,340040,OP_21,Median time to pain med,35,0.223684211,
,340085,OP_20,Door to diagnostic eval,35,0.384615385,
,340091,OP_20,Door to diagnostic eval,35,0.384615385,
,340119,OP_20,Door to diagnostic eval,35,0.384615385,
,340001,OP_20,Door to diagnostic eval,34,0.369230769,
,340047,OP_21,Median time to pain med,34,0.210526316,
,340050,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,34,0.274725275,
,340070,OP_23,Head CT results,34,0.34,
,340130,OP_20,Door to diagnostic eval,34,0.369230769,
,340183,OP_20,Door to diagnostic eval,34,0.369230769,
,341325,OP_1,Median Time to Fibrinolysis,34,0.72,
,340068,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",33,1,
,340126,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,33,0.107692308,
,340143,OP_20,Door to diagnostic eval,33,0.353846154,
,341320,OP_23,Head CT results,33,0.33,
,341325,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,33,0.107692308,
,341325,OP_20,Door to diagnostic eval,33,0.353846154,
,340027,OP_20,Door to diagnostic eval,32,0.338461538,
,340037,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,32,0.005649718,
,340109,OP_23,Head CT results,32,0.32,
,340123,OP_20,Door to diagnostic eval,32,0.338461538,
,340115,OP_20,Door to diagnostic eval,31,0.323076923,
,340116,OP_20,Door to diagnostic eval,31,0.323076923,
,340142,OP_20,Door to diagnostic eval,31,0.323076923,
,340020,OP_20,Door to diagnostic eval,30,0.307692308,
,340020,OP_3b,Median Time to Transfer to Another Facility for Acute Coronary Intervention,30,0,
,340030,OP_20,Door to diagnostic eval,30,0.307692308,
,340090,OP_20,Door to diagnostic eval,30,0.307692308,
,340096,OP_20,Door to diagnostic eval,30,0.307692308,
,340126,OP_20,Door to diagnostic eval,30,0.307692308,
,340141,OP_20,Door to diagnostic eval,30,0.307692308,
,340147,OP_1,Median Time to Fibrinolysis,30,0.56,
,340186,OP_20,Door to diagnostic eval,30,0.307692308,
,341324,OP_20,Door to diagnostic eval,30,0.307692308,
,340013,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,0.21978022,
,340028,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,0.21978022,
,340109,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,29,0.21978022,
,340114,OP_20,Door to diagnostic eval,29,0.292307692,
,340014,OP_21,Median time to pain med,28,0.131578947,
,340085,OP_21,Median time to pain med,28,0.131578947,
,340107,OP_1,Median Time to Fibrinolysis,28,0.48,
,340107,OP_20,Door to diagnostic eval,28,0.276923077,
,340151,OP_1,Median Time to Fibrinolysis,28,0.48,
,340041,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,27,0.197802198,
,340068,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,27,0.197802198,
,340075,OP_20,Door to diagnostic eval,27,0.261538462,
,340109,OP_1,Median Time to Fibrinolysis,27,0.44,
,340060,OP_20,Door to diagnostic eval,26,0.246153846,
,340084,OP_20,Door to diagnostic eval,26,0.246153846,
,340142,OP_2,Fibrinolytic Therapy Received Within 30 Minutes of ED Arrival,26,0,
,340147,OP_30,Endoscopy/polyp surveillance: colonoscopy interval for patients with a history of adenomatous polyps - avoidance of inappropriate use,26,0,
,341318,OP_20,Door to diagnostic eval,26,0.246153846,
,341324,OP_1,Median Time to Fibrinolysis,26,0.4,
,341327,OP_20,Door to diagnostic eval,26,0.246153846,
,340013,OP_1,Median Time to Fibrinolysis,24,0.32,
,340051,OP_20,Door to diagnostic eval,24,0.215384615,
,340068,OP_20,Door to diagnostic eval,24,0.215384615,
,340158,OP_21,Median time to pain med,24,0.078947368,
,340159,OP_21,Median time to pain med,24,0.078947368,
,340047,OP_20,Door to diagnostic eval,23,0.2,
,340064,OP_20,Door to diagnostic eval,23,0.2,
,340127,OP_20,Door to diagnostic eval,23,0.2,
,341304,OP_20,Door to diagnostic eval,23,0.2,
,340015,OP_21,Median time to pain med,22,0.052631579,
,340024,OP_20,Door to diagnostic eval,22,0.184615385,
,340053,OP_21,Median time to pain med,22,0.052631579,
,340061,OP_20,Door to diagnostic eval,22,0.184615385,
,340120,OP_20,Door to diagnostic eval,22,0.184615385,
,340173,OP_20,Door to diagnostic eval,22,0.184615385,
,340183,OP_21,Median time to pain med,22,0.052631579,
,340186,OP_1,Median Time to Fibrinolysis,22,0.24,
,340073,OP_20,Door to diagnostic eval,21,0.169230769,
,340087,OP_20,Door to diagnostic eval,21,0.169230769,
,340184,OP_20,Door to diagnostic eval,21,0.169230769,
,341303,OP_20,Door to diagnostic eval,21,0.169230769,
,340013,OP_20,Door to diagnostic eval,20,0.153846154,
,340032,OP_20,Door to diagnostic eval,20,0.153846154,
,340037,OP_20,Door to diagnostic eval,20,0.153846154,
,340106,OP_20,Door to diagnostic eval,20,0.153846154,
,340014,OP_20,Door to diagnostic eval,19,0.138461538,
,340071,OP_20,Door to diagnostic eval,19,0.138461538,
,340097,OP_20,Door to diagnostic eval,19,0.138461538,
,340133,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,19,0.10989011,
,340144,OP_20,Door to diagnostic eval,19,0.138461538,
,340158,OP_20,Door to diagnostic eval,19,0.138461538,
,340109,OP_20,Door to diagnostic eval,18,0.123076923,
,340132,OP_20,Door to diagnostic eval,18,0.123076923,
,340171,OP_21,Median time to pain med,18,0,
,340003,OP_20,Door to diagnostic eval,17,0.107692308,
,340023,OP_5,Median Time to ECG,17,1,
,340127,OP_5,Median Time to ECG,17,1,
,341325,OP_5,Median Time to ECG,17,1,
,340010,OP_1,Median Time to Fibrinolysis,16,0,
,340129,OP_20,Door to diagnostic eval,16,0.092307692,
,341326,OP_20,Door to diagnostic eval,16,0.092307692,
,340039,VTE_6,Hospital acquired potentially preventable venous thromboembolism,15,1,
,341320,OP_20,Door to diagnostic eval,15,0.076923077,
,340015,OP_20,Door to diagnostic eval,14,0.061538462,
,340021,OP_20,Door to diagnostic eval,14,0.061538462,
,340099,OP_5,Median Time to ECG,14,0.823529412,
,340114,VTE_6,Hospital acquired potentially preventable venous thromboembolism,14,0.933333333,
,340028,OP_20,Door to diagnostic eval,13,0.046153846,
,340099,OP_20,Door to diagnostic eval,13,0.046153846,
,340147,OP_5,Median Time to ECG,13,0.764705882,
,340186,OP_5,Median Time to ECG,13,0.764705882,
,340096,OP_5,Median Time to ECG,12,0.705882353,
,340132,OP_5,Median Time to ECG,12,0.705882353,
,340155,OP_5,Median Time to ECG,12,0.705882353,
,340159,OP_20,Door to diagnostic eval,12,0.030769231,
,340184,OP_5,Median Time to ECG,12,0.705882353,
,341319,OP_20,Door to diagnostic eval,12,0.030769231,
,341320,OP_5,Median Time to ECG,12,0.705882353,
,340003,OP_5,Median Time to ECG,11,0.647058824,
,340004,VTE_6,Hospital acquired potentially preventable venous thromboembolism,11,0.733333333,
,340016,OP_5,Median Time to ECG,11,0.647058824,
,340041,OP_5,Median Time to ECG,11,0.647058824,
,341304,OP_5,Median Time to ECG,11,0.647058824,
,340004,OP_5,Median Time to ECG,10,0.588235294,
,340016,OP_20,Door to diagnostic eval,10,0,
,340032,OP_5,Median Time to ECG,10,0.588235294,
,340042,OP_5,Median Time to ECG,10,0.588235294,
,340068,OP_5,Median Time to ECG,10,0.588235294,
,340073,OP_5,Median Time to ECG,10,0.588235294,
,340087,OP_5,Median Time to ECG,10,0.588235294,
,340113,OP_5,Median Time to ECG,10,0.588235294,
,340132,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",10,0.303030303,
,340187,OP_20,Door to diagnostic eval,10,0,
,341314,OP_20,Door to diagnostic eval,10,0,
,341316,OP_20,Door to diagnostic eval,10,0,
,341316,OP_5,Median Time to ECG,10,0.588235294,
,341318,OP_5,Median Time to ECG,10,0.588235294,
,341329,OP_20,Door to diagnostic eval,10,0,
,340024,OP_5,Median Time to ECG,9,0.529411765,
,340050,OP_5,Median Time to ECG,9,0.529411765,
,340070,OP_5,Median Time to ECG,9,0.529411765,
,340071,OP_5,Median Time to ECG,9,0.529411765,
,340075,OP_5,Median Time to ECG,9,0.529411765,
,340084,OP_29,Endoscopy/polyp surveillance: appropriate follow-up interval for normal colonoscopy in average risk patients,9,0,
,340107,OP_5,Median Time to ECG,9,0.529411765,
,341319,OP_5,Median Time to ECG,9,0.529411765,
,341328,OP_5,Median Time to ECG,9,0.529411765,
,340001,OP_5,Median Time to ECG,8,0.470588235,
,340008,OP_5,Median Time to ECG,8,0.470588235,
,340037,OP_5,Median Time to ECG,8,0.470588235,
,340050,OP_22,Left before being seen,8,1,
,340051,OP_5,Median Time to ECG,8,0.470588235,
,340091,OP_5,Median Time to ECG,8,0.470588235,
,340098,OP_5,Median Time to ECG,8,0.470588235,
,340106,OP_5,Median Time to ECG,8,0.470588235,
,340115,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",8,0.242424242,
,340123,OP_5,Median Time to ECG,8,0.470588235,
,340142,OP_5,Median Time to ECG,8,0.470588235,
,340155,VTE_6,Hospital acquired potentially preventable venous thromboembolism,8,0.533333333,
,340166,OP_5,Median Time to ECG,8,0.470588235,
,340188,OP_5,Median Time to ECG,8,0.470588235,
,340010,OP_5,Median Time to ECG,7,0.411764706,
,340028,VTE_6,Hospital acquired potentially preventable venous thromboembolism,7,0.466666667,
,340030,OP_22,Left before being seen,7,0.875,
,340060,OP_5,Median Time to ECG,7,0.411764706,
,340115,OP_5,Median Time to ECG,7,0.411764706,
,340119,OP_5,Median Time to ECG,7,0.411764706,
,340120,OP_5,Median Time to ECG,7,0.411764706,
,340126,OP_5,Median Time to ECG,7,0.411764706,
,340127,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",7,0.212121212,
,340151,OP_5,Median Time to ECG,7,0.411764706,
,340159,OP_5,Median Time to ECG,7,0.411764706,
,340186,OP_22,Left before being seen,7,0.875,
,340187,OP_5,Median Time to ECG,7,0.411764706,
,341303,OP_5,Median Time to ECG,7,0.411764706,
,341315,OP_5,Median Time to ECG,7,0.411764706,
,341326,OP_5,Median Time to ECG,7,0.411764706,
,340020,OP_5,Median Time to ECG,6,0.352941176,
,340027,OP_5,Median Time to ECG,6,0.352941176,
,340069,OP_5,Median Time to ECG,6,0.352941176,
,340143,OP_5,Median Time to ECG,6,0.352941176,
,340144,OP_5,Median Time to ECG,6,0.352941176,
,340145,OP_5,Median Time to ECG,6,0.352941176,
,340147,VTE_6,Hospital acquired potentially preventable venous thromboembolism,6,0.4,
,341329,OP_5,Median Time to ECG,6,0.352941176,
,340001,OP_22,Left before being seen,5,0.625,
,340050,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",5,0.151515152,
,340064,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",5,0.151515152,
,340090,OP_5,Median Time to ECG,5,0.294117647,
,340131,VTE_6,Hospital acquired potentially preventable venous thromboembolism,5,0.333333333,
,340133,OP_5,Median Time to ECG,5,0.294117647,
,340173,OP_5,Median Time to ECG,5,0.294117647,
,341324,OP_5,Median Time to ECG,5,0.294117647,
,340002,OP_22,Left before being seen,4,0.5,
,340013,OP_5,Median Time to ECG,4,0.235294118,
,340015,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,0.121212121,
,340017,OP_22,Left before being seen,4,0.5,
,340021,OP_5,Median Time to ECG,4,0.235294118,
,340032,OP_22,Left before being seen,4,0.5,
,340039,OP_5,Median Time to ECG,4,0.235294118,
,340040,OP_22,Left before being seen,4,0.5,
,340050,VTE_6,Hospital acquired potentially preventable venous thromboembolism,4,0.266666667,
,340061,OP_22,Left before being seen,4,0.5,
,340064,OP_5,Median Time to ECG,4,0.235294118,
,340084,OP_5,Median Time to ECG,4,0.235294118,
,340085,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,0.121212121,
,340087,OP_22,Left before being seen,4,0.5,
,340097,OP_5,Median Time to ECG,4,0.235294118,
,340113,OP_22,Left before being seen,4,0.5,
,340116,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,0.121212121,
,340123,OP_22,Left before being seen,4,0.5,
,340130,OP_5,Median Time to ECG,4,0.235294118,
,340133,OP_22,Left before being seen,4,0.5,
,340141,VTE_6,Hospital acquired potentially preventable venous thromboembolism,4,0.266666667,
,340143,OP_22,Left before being seen,4,0.5,
,340151,OP_22,Left before being seen,4,0.5,
,340171,OP_5,Median Time to ECG,4,0.235294118,
,340171,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",4,0.121212121,
,341328,OP_22,Left before being seen,4,0.5,
,340001,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,0.2,
,340004,OP_22,Left before being seen,3,0.375,
,340008,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,340013,OP_22,Left before being seen,3,0.375,
,340017,OP_5,Median Time to ECG,3,0.176470588,
,340027,OP_22,Left before being seen,3,0.375,
,340030,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,0.2,
,340042,OP_22,Left before being seen,3,0.375,
,340047,OP_22,Left before being seen,3,0.375,
,340051,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,340053,OP_22,Left before being seen,3,0.375,
,340061,VTE_6,Hospital acquired potentially preventable venous thromboembolism,3,0.2,
,340069,OP_22,Left before being seen,3,0.375,
,340070,OP_22,Left before being seen,3,0.375,
,340071,OP_22,Left before being seen,3,0.375,
,340075,OP_22,Left before being seen,3,0.375,
,340085,OP_22,Left before being seen,3,0.375,
,340090,OP_22,Left before being seen,3,0.375,
,340090,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,340098,OP_22,Left before being seen,3,0.375,
,340107,OP_22,Left before being seen,3,0.375,
,340115,OP_22,Left before being seen,3,0.375,
,340126,OP_22,Left before being seen,3,0.375,
,340141,OP_22,Left before being seen,3,0.375,
,340147,OP_22,Left before being seen,3,0.375,
,340155,OP_22,Left before being seen,3,0.375,
,340166,OP_22,Left before being seen,3,0.375,
,340173,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,340186,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,341324,OP_22,Left before being seen,3,0.375,
,341324,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",3,0.090909091,
,340001,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340003,OP_22,Left before being seen,2,0.25,
,340008,OP_22,Left before being seen,2,0.25,
,340010,OP_22,Left before being seen,2,0.25,
,340014,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340015,OP_22,Left before being seen,2,0.25,
,340015,OP_5,Median Time to ECG,2,0.117647059,
,340020,OP_22,Left before being seen,2,0.25,
,340039,OP_22,Left before being seen,2,0.25,
,340040,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340041,OP_22,Left before being seen,2,0.25,
,340051,OP_22,Left before being seen,2,0.25,
,340060,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340068,OP_22,Left before being seen,2,0.25,
,340070,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340071,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340084,OP_22,Left before being seen,2,0.25,
,340091,OP_22,Left before being seen,2,0.25,
,340096,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340098,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340106,OP_22,Left before being seen,2,0.25,
,340109,OP_22,Left before being seen,2,0.25,
,340109,OP_5,Median Time to ECG,2,0.117647059,
,340109,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340113,VTE_6,Hospital acquired potentially preventable venous thromboembolism,2,0.133333333,
,340114,OP_22,Left before being seen,2,0.25,
,340119,OP_22,Left before being seen,2,0.25,
,340120,OP_22,Left before being seen,2,0.25,
,340126,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340127,OP_22,Left before being seen,2,0.25,
,340129,OP_22,Left before being seen,2,0.25,
,340130,OP_22,Left before being seen,2,0.25,
,340131,OP_22,Left before being seen,2,0.25,
,340132,OP_22,Left before being seen,2,0.25,
,340141,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340142,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340145,OP_22,Left before being seen,2,0.25,
,340151,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",2,0.060606061,
,340158,OP_22,Left before being seen,2,0.25,
,340159,OP_22,Left before being seen,2,0.25,
,340171,OP_22,Left before being seen,2,0.25,
,340173,OP_22,Left before being seen,2,0.25,
,340183,OP_22,Left before being seen,2,0.25,
,340183,OP_5,Median Time to ECG,2,0.117647059,
,341304,OP_22,Left before being seen,2,0.25,
,340002,VTE_6,Hospital acquired potentially preventable venous thromboembolism,1,0.066666667,
,340004,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340014,OP_22,Left before being seen,1,0.125,
,340014,OP_5,Median Time to ECG,1,0.058823529,
,340016,OP_22,Left before being seen,1,0.125,
,340020,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340021,OP_22,Left before being seen,1,0.125,
,340021,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340023,OP_22,Left before being seen,1,0.125,
,340024,OP_22,Left before being seen,1,0.125,
,340037,OP_22,Left before being seen,1,0.125,
,340042,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340047,VTE_6,Hospital acquired potentially preventable venous thromboembolism,1,0.066666667,
,340053,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340060,OP_22,Left before being seen,1,0.125,
,340064,OP_22,Left before being seen,1,0.125,
,340073,OP_22,Left before being seen,1,0.125,
,340075,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340096,OP_22,Left before being seen,1,0.125,
,340099,OP_22,Left before being seen,1,0.125,
,340113,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340116,OP_22,Left before being seen,1,0.125,
,340129,OP_5,Median Time to ECG,1,0.058823529,
,340131,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",1,0.03030303,
,340142,OP_22,Left before being seen,1,0.125,
,340144,OP_22,Left before being seen,1,0.125,
,340184,OP_22,Left before being seen,1,0.125,
,341318,OP_22,Left before being seen,1,0.125,
,341319,OP_22,Left before being seen,1,0.125,
,341326,OP_22,Left before being seen,1,0.125,
,341327,OP_5,Median Time to ECG,1,0.058823529,
,341329,OP_22,Left before being seen,1,0.125,
,340002,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340003,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340010,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340010,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340013,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340014,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340015,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340016,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340017,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340023,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340024,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340027,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340027,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340028,OP_22,Left before being seen,0,0,
,340028,OP_5,Median Time to ECG,0,0,
,340028,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340030,OP_23,Head CT results,0,0,
,340030,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340032,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340032,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340039,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340040,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340041,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340053,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340061,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340069,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340069,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340070,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340073,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340085,OP_5,Median Time to ECG,0,0,
,340087,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340091,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340091,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340097,OP_22,Left before being seen,0,0,
,340097,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340098,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340099,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340107,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340114,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340115,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340116,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340119,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340120,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340123,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340129,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340130,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340133,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340142,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340143,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340144,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340145,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340147,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340151,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340155,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340158,OP_5,Median Time to ECG,0,0,
,340158,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340166,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340173,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340183,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340183,VTE_6,Hospital acquired potentially preventable venous thromboembolism,0,0,
,340184,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,340187,OP_22,Left before being seen,0,0,
,341315,ED_2b,ED2,0,0,
,341318,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,341326,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
,341329,PC_01,"Percent of newborns whose deliveries were scheduled early (1-3 weeks early), when a scheduled delivery was not medically necessary",0,0,
